Performance of the ABCD-GENE Score for Predicting Clinical Outcomes in Clopidogrel-Treated Patients with ACS
- 18 April 2022
- journal article
- research article
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 15 (6) , 1385-1392
Abstract
The ABCD-GENE score was constructed to identify patients with high platelet reactivity (HPR) after 30 days of clopidogrel treatment. In our study, 1297 eligible patients with acute coronary syndrome (ACS) were included, and 44 (3.4%) major adverse cardiovascular events (MACEs) occurred during the 12-month clopidogrel treatment. The score with a cutoff of ≥ 10 was independently associated with the risk of 5-day HPR (adjusted HR: 1.73, 95% CI: 1.09–2.74, P = 0.020) and MACEs (adjusted HR: 2.25, 95% CI: 1.19–4.25, P = 0.013). The risk of MACEs increased when the multivariable model with the score (≥ 10) plus 5-day HPR was used (adjusted HR: 4.37, 95% CI: 1.90–10.10, P = 0.001). The c-statistic for MACEs was 0.60 when using the score threshold of ≥ 10 and 0.63 when using the model with the score plus 5-day HPR. As a simple tool, the ABCD-GENE score could identify clopidogrel-treated Chinese patients with ACS who are at increased risk of MACEs. The addition of 5-day HPR could slightly improve the diagnostic ability of the score. Graphical abstractKeywords
Funding Information
- Natural Science Foundation of China (81870262)
This publication has 39 references indexed in Scilit:
- 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial InfarctionCirculation, 2013
- Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary InterventionCirculation, 2011
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010
- Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine DiphosphateJACC, 2010
- Adenosine diphosphate–induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic eventsAmerican Heart Journal, 2010
- Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyThe Lancet, 2010
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Clopidogrel for Coronary StentingCirculation, 2003